MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
July 27, 2022 08:30 ET
|
MiNK Therapeutics
NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
May 25, 2022 08:30 ET
|
MiNK Therapeutics
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
May 10, 2022 08:00 ET
|
MiNK Therapeutics
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000 doses/yrBCMA-CAR-iNKT and stromal-CAR-iNKT...
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update
April 27, 2022 17:19 ET
|
MiNK Therapeutics
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 18, 2022 08:30 ET
|
MiNK Therapeutics
AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancersBenefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTsAgenT-797 treatment with...
MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update
March 03, 2022 16:35 ET
|
MiNK Therapeutics
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers
March 03, 2022 09:28 ET
|
MiNK Therapeutics
Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicityClinical trials underway in solid tumor cancers,...
MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference
January 12, 2022 09:41 ET
|
MiNK Therapeutics
NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 17, 2021 16:15 ET
|
MiNK Therapeutics
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797
November 12, 2021 07:00 ET
|
MiNK Therapeutics
No evidence of neurotoxicity or cytokine release syndromeEarly signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myelomaiNKTs...